Pretreating ovarian cancer patients with cyclophosphamide before p53-SLP immunization was also attempted, and, while the study showed a strong p53 immune response, only 2 of the 10 patients involved in the study responded with a stable disease (no complete/partial response, no disease progression) after treatment [136]. The gene discussed is TP53; the disease is ovarian cancer.